Proximie raises $38M in Series B round
23 Apr 2021
Digital surgery company Proximie this week announced it has raised $38 million in a Series B equity financing round.
F-Prime Capital led the round, with participation from new investors Questa Capital, Eight Roads, Maverick Ventures. There was also support from existing investors Global Ventures, BECO Capital and Cedar Mundi Ventures.
Proximie’s platform uses augmented reality (AR), machine learning (ML), artificial intelligence (AI) and advanced telecommunications to enable physicians and surgeons to interact globally during surgical and diagnostic procedures. The London-based company said it has conducted more than 10,000 surgical interactions in 300 hospitals in over 40 countries in the past year. Every interaction is captured, digitized, cataloged, and analyzed, according to the company.
Proximie said it will use the proceeds to accelerate its expansion in the U.S. and European markets. Significant investment will be directed toward commercial efforts, including new technology implementations, in addition to research and development.
“We are delighted to be working with this distinguished group of new investors and are thrilled by the continued support from our existing shareholders,” said Proximie founder and CEO Dr. Nadine Hachach-Haram in a news release. “This investment will fuel our growth and gives our platform the opportunity to revolutionize an important area of unmet need in the healthcare sector.”
“To have secured investment from the likes of F-Prime, Questa, Eight Roads and Maverick, along with the support of existing shareholders, is a huge achievement for the team at Proximie,” added veteran medtech executive Scott Huennekens, an advisor to Hachach-Haram and the Proximie board. “The future of healthcare will be shaped by innovative technology and Proximie is at the forefront of this movement. Not only does this investment validate Nadine’s foresight, vision and operational execution, it also reflects the market opportunity for Proximie’s innovative platform to revolutionize global healthcare.”
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.